House A K, Watt A G
Gut. 1979 Oct;20(10):868-74. doi: 10.1136/gut.20.10.868.
One hundred and seven patients with colorectal carcinoma were examined for their immune response to autologous tumour. Patient leucocyte migration inhibition by tumour antigen, migration inhibition of normal subject's leucocytes by patient's serum, and the assessment of lymphocyte invasion of the tumour specimen were used to measure the immune response. Forty-one and 51% of patients were immune by leucocyte migration inhibition and tumour invasion by lymphocytes respectively. The immune patients had a survival advantage at three years on Chi-squared analysis. Patients whose serum contained a factor that inhibited the migration of leucocytes obtained from normal individuals had a diminished survival prognosis. The donors of these sera had a 50% chance of dying or of developing recurrent disease. These same individuals represented 30% of all those tested by this method. The immune patients included the sera donors as a subgroup 30% of all those tested by this method. The immune patients included the sera donors as a subgroup who, if excluded from the life table analysis, left a group of immune subjects who had very superior survival features.
对107例结肠直肠癌患者进行了自体肿瘤免疫反应检测。采用肿瘤抗原抑制患者白细胞迁移、患者血清抑制正常受试者白细胞迁移以及评估肿瘤标本中的淋巴细胞浸润情况来衡量免疫反应。分别有41%和51%的患者通过白细胞迁移抑制和淋巴细胞浸润表现出免疫反应。经卡方分析，免疫患者在三年时有生存优势。血清中含有抑制正常个体白细胞迁移因子的患者生存预后较差。这些血清供体有50%的死亡或复发疾病几率。这些个体占通过该方法检测的所有个体的30%。免疫患者包括血清供体这一亚组，占通过该方法检测的所有个体的30%。免疫患者包括血清供体这一亚组，如果在生命表分析中排除该亚组，剩下的免疫受试者组具有非常优越的生存特征。
